JP2018522013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522013A5 JP2018522013A5 JP2018502404A JP2018502404A JP2018522013A5 JP 2018522013 A5 JP2018522013 A5 JP 2018522013A5 JP 2018502404 A JP2018502404 A JP 2018502404A JP 2018502404 A JP2018502404 A JP 2018502404A JP 2018522013 A5 JP2018522013 A5 JP 2018522013A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- composition according
- acid polymer
- truncated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 20
- 102000039446 nucleic acids Human genes 0.000 claims 20
- 229920000642 polymer Polymers 0.000 claims 17
- 101150117329 NTRK3 gene Proteins 0.000 claims 11
- 101150056950 Ntrk2 gene Proteins 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229920001983 poloxamer Polymers 0.000 claims 4
- 229960000502 poloxamer Drugs 0.000 claims 4
- 208000032625 disorder of ear Diseases 0.000 claims 3
- 239000002679 microRNA Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 2
- -1 Ethylene nucleic acid Chemical class 0.000 claims 2
- 208000027530 Meniere disease Diseases 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 206010011891 Deafness neurosensory Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 206010063491 Herpes zoster oticus Diseases 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- IKRKJHFXRDRMDN-UHFFFAOYSA-N OP(OCN1CCOCC1)=O Chemical class OP(OCN1CCOCC1)=O IKRKJHFXRDRMDN-UHFFFAOYSA-N 0.000 claims 1
- 206010033109 Ototoxicity Diseases 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 208000005457 endolymphatic hydrops Diseases 0.000 claims 1
- 230000003492 excitotoxic effect Effects 0.000 claims 1
- 231100000063 excitotoxicity Toxicity 0.000 claims 1
- 201000011349 geniculate herpes zoster Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 231100000262 ototoxicity Toxicity 0.000 claims 1
- 150000008300 phosphoramidites Chemical class 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198062P | 2015-07-28 | 2015-07-28 | |
| US62/198,062 | 2015-07-28 | ||
| PCT/US2016/044570 WO2017019905A1 (en) | 2015-07-28 | 2016-07-28 | Treatment using truncated trk b and trk c antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522013A JP2018522013A (ja) | 2018-08-09 |
| JP2018522013A5 true JP2018522013A5 (enExample) | 2019-09-05 |
| JP6923509B2 JP6923509B2 (ja) | 2021-08-18 |
Family
ID=57884960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502404A Active JP6923509B2 (ja) | 2015-07-28 | 2016-07-28 | 切断型のｔｒｋｂおよびｔｒｋｃのアンタゴニストを使用する処置 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10066229B2 (enExample) |
| EP (1) | EP3328440A4 (enExample) |
| JP (1) | JP6923509B2 (enExample) |
| WO (1) | WO2017019905A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
| EP3406259A1 (en) * | 2017-05-24 | 2018-11-28 | Dompé farmaceutici S.p.A. | Neurotrophins for use in the treatment of hearing loss |
| EP3820483A4 (en) * | 2018-07-13 | 2023-03-01 | Yale University | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ENDOMETRIOSIS |
| US11911416B2 (en) | 2018-08-01 | 2024-02-27 | University Of Iowa Research Foundation | Compositions and methods to restore hearing loss and balance through embryonic ear transplant |
| EP3891273A1 (en) * | 2018-12-04 | 2021-10-13 | Sirion Biotech GmbH | Viral transduction using poloxamines |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| DK0604552T3 (da) | 1991-09-18 | 1997-08-04 | Affymax Tech Nv | Fremgangsmåde til syntese af forskellige samlinger af oligomerer |
| US5677195A (en) | 1991-11-22 | 1997-10-14 | Affymax Technologies N.V. | Combinatorial strategies for polymer synthesis |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
| AU720232B2 (en) | 1996-07-19 | 2000-05-25 | Amgen, Inc. | Analogs of cationic proteins |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| AU1287799A (en) | 1997-10-31 | 1999-05-24 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
| US6020135A (en) | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
| US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
| US20060148749A1 (en) | 2002-02-22 | 2006-07-06 | University Of Maryland | Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
| AU2002257333A1 (en) * | 2002-02-22 | 2003-09-09 | Linda L. Bambrick | Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| US20050095246A1 (en) * | 2003-10-24 | 2005-05-05 | Medtronic, Inc. | Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators |
| EP1752536A4 (en) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME |
| DE102005004343A1 (de) * | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| ES2569881T3 (es) * | 2005-06-08 | 2016-05-12 | The University Of North Carolina At Chapel Hill | Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos |
| JP5674469B2 (ja) * | 2007-10-11 | 2015-02-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法 |
| US20120004310A1 (en) | 2010-05-28 | 2012-01-05 | Longo Frank M | Non-peptide bdnf neurotrophin mimetics |
| KR20140024270A (ko) | 2010-12-30 | 2014-02-28 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| ES2479815B1 (es) * | 2012-12-24 | 2015-05-06 | Consejo Superior De Investigaciones Cientificas (Csic) | Peptido neuroprotector asi como su uso en el tratamiento de enfermedades cerebrovasculares y otras patologias del snc |
| USRE50566E1 (en) * | 2013-10-28 | 2025-09-02 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for modulating neuronal excitability and motor behavior |
| US10066229B2 (en) | 2015-07-28 | 2018-09-04 | Otonomy, Inc. | Treatment using truncated Trk B and Trk C antagonists |
-
2016
- 2016-07-28 US US15/222,710 patent/US10066229B2/en active Active
- 2016-07-28 WO PCT/US2016/044570 patent/WO2017019905A1/en not_active Ceased
- 2016-07-28 EP EP16831375.7A patent/EP3328440A4/en not_active Ceased
- 2016-07-28 JP JP2018502404A patent/JP6923509B2/ja active Active
-
2018
- 2018-07-20 US US16/041,638 patent/US11034961B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2969371T3 (es) | Interferencia por ARN para el tratamiento de trastornos de ganancia de función | |
| US20210139905A1 (en) | Oligonucleotide therapy for leber congenital amaurosis | |
| CN114514038B (zh) | 胶束纳米颗粒及其用途 | |
| IL272761B1 (en) | Antisense oligomers for treatment of conditions and diseases | |
| JP2021526837A5 (enExample) | ||
| US11352626B2 (en) | Oligonucleotides matching COL7A1 exon 73 for epidermolysis bullosa therapy | |
| CN103080314A (zh) | 显性突变基因表达抑制剂 | |
| US20060160759A1 (en) | Influenza therapeutic | |
| PE20220561A1 (es) | Metodos para el tratamiento de infeccion de hepatitis b | |
| JP2018523668A5 (enExample) | ||
| JP2018512060A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| JP2009535039A5 (enExample) | ||
| US20170233742A1 (en) | Compositions Comprising Small Interfering RNA Molecules for Prevention and Treatment of Ebola Virus Disease | |
| KR20210144601A (ko) | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 | |
| WO2023023597A1 (en) | Virus-like particle | |
| CN106999573A (zh) | 佐剂组合物 | |
| JP2023532536A (ja) | ｍｉＲＮＡ－４８５ハンチントン病の阻害剤 | |
| CN104245936B (zh) | 用于抑制TGF-β2表达的shRNA | |
| Wu et al. | Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics | |
| WO2020116537A1 (ja) | がん処置用ＲＮＡｉ分子 | |
| US10731161B2 (en) | Influenza-activated constructs and methods of use thereof | |
| JP2018513841A5 (enExample) | ||
| Zhou et al. | Mechanisms and barriers to RNAi delivery | |
| US20170183653A1 (en) | Pri-mirna libraries and methods for making and using pri-mirna libraries |